Fig. 6

Effect of CD200 deficiency on MPTP-induced dopaminergic neurodegeneration and microglial activation at day 1 after administration. Mice were injected intraperitoneally with saline or MPTP (18 mg/kg) every 2 h to a total of 4 doses in one day. Mice were sacrificed 1 day after the last MPTP injection and brains were fixed for immunohistochemistry. a TH immunostaining in striatum and optical densitometry of striatal TH-positive dopaminergic fibers of saline- and MPTP-treated CD200 +/+ and CD200 −/− mice. b TH immunostaining and stereological cell counts of dopaminergic neurons in the substantia nigra pars compacta (SNpc) of saline- and MPTP-treated CD200 +/+ and CD200 −/− mice. c Representative photomicrographs of IBA1-immunostained substantia nigra (SN) of CD200 +/+ and CD200 −/− mice treated with saline or MPTP. Quantification of the IBA1-labelled area (d), the immunolabelling intensity of IBA1-positive cells (e) and the total number of IBA1-positive cells in total SN and SNpc of saline- and MPTP-treated CD200 +/+ and CD200 −/− mice. Bars are means + SEM of five to eleven mice per experimental group. *p < 0.05, **p < 0.01 and ***p < 0.001 vs. saline; ##p < 0.01 vs. CD200 +/+ MPTP-treated mice; two-way ANOVA and Bonferroni post hoc test. Scale bars: 500 μm (striatum) and 200 μm (SN and SNpc)